Literature DB >> 18772159

CTX-M-15-producing Escherichia coli in fatal neonatal meningitis: failure of empirical chemotherapy.

Sophie Boyer-Mariotte, Pauline Duboc, Stéphane Bonacorsi, Jean-François Lemeland, Edouard Bingen, Didier Pinquier.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772159     DOI: 10.1093/jac/dkn362

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  15 in total

1.  Community-associated Escherichia coli harboring CTX-M β-lactamases from urine cultures from pediatric patients.

Authors:  Krystina L Woods; James R Johnson; Sofia Padkowsky; Noriel Mariano; Rita Colon-Urban; Mahmoud Hassanein; Wehbeh Wehbeh; Brian D Johnston; Connie Clabots; Saadia Zahid; Carl Urban
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

2.  Deciphering the roles of outer membrane protein A extracellular loops in the pathogenesis of Escherichia coli K1 meningitis.

Authors:  Rahul Mittal; Subramanian Krishnan; Ignacio Gonzalez-Gomez; Nemani V Prasadarao
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

3.  Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care [Formula: see text]-Lactamase Characterization.

Authors:  Akilan Palanisami; Shazia Khan; Sultan Sibel Erdem; Tayyaba Hasan
Journal:  IEEE J Transl Eng Health Med       Date:  2016-06-29       Impact factor: 3.316

4.  Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15.

Authors:  Flavie Pouillot; Maryline Chomton; Hélène Blois; Celine Courroux; Julien Noelig; Philippe Bidet; Edouard Bingen; Stéphane Bonacorsi
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

5.  Meningitis caused by Escherichia coli producing TEM-52 extended-spectrum beta-lactamase within an extensive outbreak in a neonatal ward: epidemiological investigation and characterization of the strain.

Authors:  Didier Moissenet; Béatrice Salauze; Olivier Clermont; Edouard Bingen; Guillaume Arlet; Erick Denamur; Audrey Mérens; Delphine Mitanchez; Hoang Vu-Thien
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

6.  IL-10 administration reduces PGE-2 levels and promotes CR3-mediated clearance of Escherichia coli K1 by phagocytes in meningitis.

Authors:  Rahul Mittal; Ignacio Gonzalez-Gomez; Ashok Panigrahy; Kerstin Goth; Richard Bonnet; Nemani V Prasadarao
Journal:  J Exp Med       Date:  2010-05-24       Impact factor: 14.307

7.  Resistance of the brain to Escherichia coli K1 infection depends on MyD88 signaling and the contribution of neutrophils and monocytes.

Authors:  Sandra Ribes; Tommy Regen; Tanja Meister; Simone C Tauber; Sandra Schütze; Alexander Mildner; Matthias Mack; Uwe-Karsten Hanisch; Roland Nau
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

8.  Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis.

Authors:  Rahul Mittal; Ignacio Gonzalez-Gomez; Kerstin A Goth; Nemani V Prasadarao
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

9.  Characterization of extended-spectrum-beta-lactamase-producing Escherichia coli strains involved in maternal-fetal colonization: prevalence of E. coli ST131.

Authors:  André Birgy; Patricia Mariani-Kurkdjian; Philippe Bidet; Catherine Doit; Nathalie Genel; Céline Courroux; Guillaume Arlet; Edouard Bingen
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948

10.  Evaluation of cefotaxime and desacetylcefotaxime concentrations in cord blood after intrapartum prophylaxis with cefotaxime.

Authors:  Jacques Lepercq; Jean Marc Treluyer; Christelle Auger; Josette Raymond; Elisabeth Rey; Thomas Schmitz; Vincent Jullien
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.